Enlivex to Present at Upcoming Investor and Media Conferences
Nes-Ziona, Israel, Sept. 13, 2022 (GLOBE NEWSWIRE) — Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”),…
Nes-Ziona, Israel, Sept. 13, 2022 (GLOBE NEWSWIRE) — Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”),…
Nes-Ziona, Israel, Sept. 13, 2022 (GLOBE NEWSWIRE) — Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”),…
Phase 2 trial expected to enroll 210 patients at approximately 75 sites to evaluate antiviral…
Phase 2 trial expected to enroll 210 patients at approximately 75 sites to evaluate antiviral…
Marks first randomized Phase 2/3 trial of CRISPR-enhanced bacteriophage precision medicine RESEARCH TRIANGLE PARK, N.C.,…
Marks first randomized Phase 2/3 trial of CRISPR-enhanced bacteriophage precision medicine RESEARCH TRIANGLE PARK, N.C.,…
FRTX-02 has been well tolerated in completed SAD cohorts; dosing of remaining SAD cohorts to…
FRTX-02 has been well tolerated in completed SAD cohorts; dosing of remaining SAD cohorts to…
HOUSTON, Sept. 13, 2022 (GLOBE NEWSWIRE) — Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical…
HOUSTON, Sept. 13, 2022 (GLOBE NEWSWIRE) — Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical…
Second Fast Track designation for efzofitimod clinical program. Efzofitimod previously received FDA orphan drug designation…
Second Fast Track designation for efzofitimod clinical program. Efzofitimod previously received FDA orphan drug designation…
Standardized methodology demonstrates high presence of placental membrane growth factors in BioStem’s Vendaje® and Vendaje…
Standardized methodology demonstrates high presence of placental membrane growth factors in BioStem’s Vendaje® and Vendaje…
NEW YORK, Sept. 13, 2022 (GLOBE NEWSWIRE) — IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical…
NEW YORK, Sept. 13, 2022 (GLOBE NEWSWIRE) — IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical…
NEW YORK and CLEVELAND, Sept. 13, 2022 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO)…
NEW YORK and CLEVELAND, Sept. 13, 2022 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO)…
New director brings big pharma oncology experience and biotech leadership SAN DIEGO and TORONTO, Sept….
New director brings big pharma oncology experience and biotech leadership SAN DIEGO and TORONTO, Sept….